These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 17292559)
1. Exenatide and biotin in conjunction with a protein-sparing fast for normalization of beta cell function in type 2 diabetics. McCarty MF Med Hypotheses; 2007; 69(4):928-32. PubMed ID: 17292559 [TBL] [Abstract][Full Text] [Related]
2. Effects of exenatide and metformin in combination on some adipocytokine levels: a comparison with metformin monotherapy. Derosa G; Cicero AF; Franzetti IG; Querci F; Carbone A; Ciccarelli L; D'Angelo A; Fogari E; Maffioli P Can J Physiol Pharmacol; 2013 Sep; 91(9):724-32. PubMed ID: 23984793 [TBL] [Abstract][Full Text] [Related]
3. Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: a randomized placebo-controlled trial. Derosa G; Franzetti IG; Querci F; Carbone A; Ciccarelli L; Piccinni MN; Fogari E; Maffioli P Pharmacotherapy; 2013 Aug; 33(8):817-26. PubMed ID: 23744726 [TBL] [Abstract][Full Text] [Related]
4. Leptin restores the insulinotropic effect of exenatide in a mouse model of type 2 diabetes with increased adiposity induced by streptozotocin and high-fat diet. Sakai T; Kusakabe T; Ebihara K; Aotani D; Yamamoto-Kataoka S; Zhao M; Gumbilai VM; Ebihara C; Aizawa-Abe M; Yamamoto Y; Noguchi M; Fujikura J; Hosoda K; Inagaki N; Nakao K Am J Physiol Endocrinol Metab; 2014 Oct; 307(8):E712-9. PubMed ID: 25159327 [TBL] [Abstract][Full Text] [Related]
5. Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide. van Genugten RE; van Raalte DH; Diamant M Diabetes Res Clin Pract; 2009 Dec; 86 Suppl 1():S26-34. PubMed ID: 20115929 [TBL] [Abstract][Full Text] [Related]
6. beta-cell failure in diabetes and preservation by clinical treatment. Wajchenberg BL Endocr Rev; 2007 Apr; 28(2):187-218. PubMed ID: 17353295 [TBL] [Abstract][Full Text] [Related]
7. Comparison of independent and combined metabolic effects of chronic treatment with (pGlu-Gln)-CCK-8 and long-acting GLP-1 and GIP mimetics in high fat-fed mice. Irwin N; Hunter K; Montgomery IA; Flatt PR Diabetes Obes Metab; 2013 Jul; 15(7):650-9. PubMed ID: 23388064 [TBL] [Abstract][Full Text] [Related]
8. The effects of glucagon-like peptide-1 on the beta cell. Vilsbøll T Diabetes Obes Metab; 2009 Dec; 11 Suppl 3():11-8. PubMed ID: 19878257 [TBL] [Abstract][Full Text] [Related]
9. Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data. Gallwitz B Int J Clin Pract; 2006 Dec; 60(12):1654-61. PubMed ID: 17109672 [TBL] [Abstract][Full Text] [Related]
10. [New drugs; exenatide and sitagliptin]. van Bronswijk H; Dubois EA; Pijl H; Cohen AF Ned Tijdschr Geneeskd; 2008 Apr; 152(15):876-9. PubMed ID: 18512528 [TBL] [Abstract][Full Text] [Related]
11. Exenatide plus metformin compared with metformin alone on β-cell function in patients with Type 2 diabetes. Derosa G; Franzetti IG; Querci F; Carbone A; Ciccarelli L; Piccinni MN; Fogari E; Maffioli P Diabet Med; 2012 Dec; 29(12):1515-23. PubMed ID: 22540883 [TBL] [Abstract][Full Text] [Related]
12. [Exenatide--an incretin-mimetic agent for the treatment of type 2 diabetes mellitus]. Reuter H; Erdmann E Dtsch Med Wochenschr; 2007 Mar; 132(11):571-4. PubMed ID: 17342635 [TBL] [Abstract][Full Text] [Related]
13. Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes. Rother KI; Spain LM; Wesley RA; Digon BJ; Baron A; Chen K; Nelson P; Dosch HM; Palmer JP; Brooks-Worrell B; Ring M; Harlan DM Diabetes Care; 2009 Dec; 32(12):2251-7. PubMed ID: 19808924 [TBL] [Abstract][Full Text] [Related]
14. Exenatide: its position in the treatment of type 2 diabetes. Guerci B; Martin CS Ann Endocrinol (Paris); 2008 Jun; 69(3):201-9. PubMed ID: 18533126 [TBL] [Abstract][Full Text] [Related]
15. Stabilizing effect of exenatide in a patient with C-peptide-negative diabetes mellitus. Paisley AN; Savage MW; Wiles PG Diabet Med; 2009 Sep; 26(9):935-8. PubMed ID: 19719716 [TBL] [Abstract][Full Text] [Related]
17. Exenatide improves weight loss insulin sensitivity and β-cell function following administration to a type 2 diabetic HIV patient on antiretroviral therapy. Oriot P; Hermans MP; Selvais P; Buysschaert M; de la Tribonnière X Ann Endocrinol (Paris); 2011 Jun; 72(3):244-6. PubMed ID: 21652029 [TBL] [Abstract][Full Text] [Related]
18. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. Fehse F; Trautmann M; Holst JJ; Halseth AE; Nanayakkara N; Nielsen LL; Fineman MS; Kim DD; Nauck MA J Clin Endocrinol Metab; 2005 Nov; 90(11):5991-7. PubMed ID: 16144950 [TBL] [Abstract][Full Text] [Related]
19. Incretin-based therapy and the quest for sustained improvements in β-cell health. Drucker DJ Diabetes Care; 2011 Sep; 34(9):2133-5. PubMed ID: 21868783 [No Abstract] [Full Text] [Related]
20. Exenatide improves β-cell function up to 3 years of treatment in patients with type 2 diabetes: a randomised controlled trial. van Raalte DH; Bunck MC; Smits MM; Hoekstra T; Cornér A; Diamant M; Eliasson B; Marja-RiittaTaskinen ; Heine RJ; Smith U; HanneleYki-Järvinen ; Mari A Eur J Endocrinol; 2016 Oct; 175(4):345-52. PubMed ID: 27466218 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]